Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

Banach, Maciej; Şerban, Corina; Sahebkar, Amirhossein; Mikhailidis, Dimitri P.; Ursoniu, Sorin; Ray, Kausik K.; Rysz, Jacek; Tóth, Peter P.; Muntner, Paul; Moşteoru, Svetlana; García‐García, Héctor M.; Hovingh, G. Kees; Kastelein, John J.P.; Serruys, Patrick W.

doi:10.1186/s12916-015-0459-4

Cited by 187 publications

(130 citation statements)

References 48 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Simvastatin would also inhibit the biosynthesis of isoprenoid intermediates such as geranyl and farnesyl pyrophosphate, and then affect the posttranslational prenylation of several important cellsignaling proteins during immune responses [11]. Therefore, simvastatin has been shown to have antitumor potential in many different cell lines [12][13][14].…”

Section: Discussionmentioning

confidence: 99%

The Effect of High-Dose Simvastatin Therapy on Patients with Acute Cerebral Infarction

Liu¹,

Hang²,

Li³

et al. 2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Cerebrovascular disease (CVD) accounts for the major cause of morbidity and mortality in industrialized countries. However, effects of high-dose simvastatin therapy on patients with acute cerebral infarction still unclear. In this study, the clinical efficacy of high-dose simvastatin on patients with cerebral infarction was investigated. A total of 180 patients with acute cerebral infarction were randomized divided into control group (n=60), high-dose simvastatin (HDS) group (n=60) and low-dose simvastatin (LDS) group (n=60). Control group, HDS group and LDS group received conventional treatment, conventional treatment together with simvastatin 80 mg/d and conventional treatment as well as simvastatin 40 mg/d respectively for 3 months. Biochemical indices, neurological deficit and plaque thickness and volume were assessed and recorded after treatment. After simvastatin treatment, the plasma levels of Triglyceride, Total cholesterol, Low-density lipoprotein were significantly decreased in HDS group and LDS group, and HDS were significantly increased in HDS group and LDS group. Also, simvastatin decreased levels of IL-6 and TNF-α, two major inflammatory factors in plasma. Furthermore, improved neurological deficit were found in simvastatin treatment groups. In addition, simvastatin treatment also improved plaque states include plaque thickness and volume in HDS group and LDS group. Therefore, simvastatin could improve acute cerebral infarction and high-dose of simvastatin treatment was better than low -dose of simvastatin treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of High-Dose Simvastatin Therapy on Patients with Acute Cerebral Infarction

Liu¹,

Hang²,

Li³

et al. 2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

show abstract

“…Reduction in further build up and thickening of atherosclerotic plaques, as well as effects on external elastic membranes and fibrous and dense calcium volumes is achieved by statin therapy (Banach et al 2015). Dual antiplatelet therapies using cyclooxygenase inhibitors such as aspirin and P2Y12 inhibitor such as clopidogrel are first-line treatments for prevention of CVDs, which aim to reduce clot formation and platelet aggregation (Kapil et al 2017).…”

Section: Introductionmentioning

confidence: 99%

The use of nanotechnology in cardiovascular disease

2018

View full text Add to dashboard Cite

Cardiovascular diseases claim a number of lives globally; many of which are preventable. With the increase in diets that consist of high saturated fat, salt, and sugar, people often living sedentary lifestyles, and a rise in cases of obesity, the incidence of cardiovascular disease is increasing. These contributing factors, coupled with more advanced methods of diagnosis, have delivered statistics that clearly show that there is a rising trend in the prevalence of cardiovascular disease. Treatment for cardiovascular diseases is limited currently to oral medicines or invasive surgery. There is a huge gap in this area of medicine for novel therapeutics for improved patient outcomes. Nanotechnology may provide a solution to more effective treatment of disease, with better prognoses and a reduced side effect profile. This review will explore for potential solutions to the limited pharmacological therapies currently on the market and the future that lies ahead for the place of nanotechnology within cardiovascular medicine.

show abstract

“…Besides their lipid-lowering effects, statins exhibit pleiotropic properties such as anti-inflammatory [10] , antioxidant [11] , antihypertrophic and antifibrotic effects, which might play a role in CV protection [12] . Statins can slow the progression or even induce regression of atherosclerosis [13] , which may reduce myocardial ischemia, which can cause ventricular arrhythmias, and in consequence reduce the risk of SCD [14] . Large scale clinical trials indicated that statins reduce CV morbidity and mortality in high-risk populations [15] .…”

Section: Introductionmentioning

confidence: 99%